How do you combine high-precision MedTech innovation with a complex shareholder structure? CANTREAT AG shows how it’s done. While the startup is rethinking cancer treatment with magnetically controlled nanoparticles, Konsento ensures clear, efficient and legally compliant processes in the background—from digital share register to general meetings and capital measures. This allows CANTREAT to fully focus on research, development and growth.
A technology platform driven by vision and purpose
The Company
CANTREAT AG, based in Freienbach (SZ), is one of the most innovative MedTech startups in Switzerland. Founded in 2023 by Thomas Steinmüller, Dietmar Hold and Michael Forster, the interdisciplinary founding team pursues an ambitious goal: to transform cancer treatment so that it becomes more targeted, more effective and significantly more tolerable for patients.
At the core is not a new substance, but a radically new approach: magnetically controllable nanoparticles that deliver already approved chemotherapeutic agents directly into the tumor—without unnecessarily affecting the rest of the body. CANTREAT’s medical device works exactly where it is needed. Precise. Effective. With significantly fewer side effects.
Instead of following the lengthy path of developing new drugs, the company accelerates the application of existing substances through intelligent drug targeting—an approach that benefits both patients and the healthcare system. Up to 90% of all available cytostatics can be combined with CANTREAT’s technology, including many that were previously hardly usable due to severe side effects.
High-precision medicine meets a growing company
Traditional chemotherapy works non-specifically throughout the body: it attacks tumor cells, but also damages healthy tissue. The result is significant side effects, reduced quality of life and long recovery periods. Active substances often only partially reach the tumor, while a large proportion is distributed throughout the rest of the body—limiting dosage, effectiveness and applicability in complex tumor cases.
CANTREAT’s answer is a platform technology that delivers existing drugs precisely where they are needed—while protecting healthy cells. The mechanism: the tumor recognizes the nanoparticle coating as an energy source, absorbs it—and with it, unnoticed, the attached cytostatic agent.
“Our vision is clear: treat cancer in a targeted way—while remaining gentle on life. Today, millions of cancer patients suffer not only from the disease itself, but also from the severe side effects of therapy. With CANTREAT, the active substance is meant to act only where it is needed—resulting in fewer side effects, better tolerability and potentially higher chances of recovery.” Thomas Steinmüller
At the same time, the company faced a fundamental entrepreneurial challenge early on: how can a young, research-driven startup with more than 120 shareholders maintain full control? How can share transfers, general meetings and capital measures be handled cleanly, efficiently and in full legal compliance—without distracting from the core mission?
The goal: focus on innovation, not administration
CANTREAT’s overarching goal is to improve existing cancer therapies so they become more precise, more effective and better tolerated by patients. Strategically, the company deliberately avoids developing new active substances and instead focuses on a platform technology that can be combined with the majority of approved chemotherapeutics. This reduces development timelines, lowers regulatory hurdles and enables faster clinical application.
From a corporate governance perspective, this means one thing: management must be able to focus on research, development and partnerships—without being burdened by administrative processes, media disruptions or complex coordination efforts around corporate actions.
In short, the goal is clear: give the management team the freedom to focus on what truly matters—research, clinical development and strategic growth.
The solution: digital shareholder management and corporate actions in one system
CANTREAT adopted the Konsento platform early on and uses it extensively. With more than 120 shareholders, the digital share register ensures that the ownership structure is always legally compliant, up to date and fully transparent. Share transfers—whether between shareholders or involving the company—are handled entirely digitally. Konsento automatically generates the required assignment declarations and prepares them for qualified electronic signatures (QES).
Signed assignments are directly linked to the respective transaction. This creates a seamless, audit-proof ownership chain—protecting CANTREAT from valuation losses or delays during due diligence in future financing rounds or a potential exit.
CANTREAT also conducts all general meetings via Konsento—both ordinary and extraordinary. For example, an extraordinary general meeting was used to approve a relocation of the company’s registered office. The platform enabled the company to efficiently collect approvals from more than 120 shareholders in a structured and legally reliable manner—including online notarization. Konsento handled the complete document preparation as well as the commercial register filing.
Another key example is the subsequent capital contribution (Nachliberierung): from the board resolution and amendment of the articles of association to document generation, notarization and commercial register filing, the entire process was executed digitally and fully integrated via Konsento.
“What convinced us was the combination of legal certainty and simplicity. Traditional advisory solutions mean: call, email, wait, invoice—Konsento means: start the process, follow step by step, done.” Thomas Steinmüller
The implementation: legally compliant, fast and scalable
The strength of the solution lies not in individual features, but in how they work together:
- Digital share register with complete transaction and document history
- Automated document generation for share transfers, shareholder and board resolutions
- Qualified electronic signatures (QES) without media disruption
- Structured handling of complex corporate actions—even with a large shareholder base
- Full organization, convening, execution and documentation of general meetings and board meetings in one system
- Direct commercial register filings after resolutions—without external coordination
In all cases, the Konsento platform replaces traditional, time-consuming advisory and coordination efforts, enabling fast, cost-efficient and legally compliant execution.
“For me personally, it’s the time savings and the clarity—I always know who the shareholders are, which resolutions have been passed and what comes next. For CANTREAT as a company, it’s about legal certainty and cost efficiency: we have significantly reduced external legal and notary costs while improving the quality of our corporate governance. That’s a real competitive advantage—especially when dealing with professional investors who look closely.” Dietmar Hold
Medical progress with corporate clarity
CANTREAT demonstrates how medical excellence and strong corporate structures can go hand in hand. The founders have not only developed a powerful technological vision, but also built the organizational foundation needed to support it. Legal compliance, transparency and efficiency are not ends in themselves—but essential prerequisites for impactful innovation.
Our conclusion: precision in corporate management, too
CANTREAT shows that technological innovation should not stop at medical application. Those who strive for precision in therapy also need precision in corporate management. With Konsento, CANTREAT has chosen a solution that reduces legal complexity without compromising substance—freeing up resources for what truly matters: meaningful medical progress for patients.
The founders are not only rethinking cancer treatment—but also how a modern, ambitious company in Switzerland should be run. A model worth following.
Key Facts – CANTREAT AG at a glance
- Founded: 2023
- Location: Freienbach (SZ), Switzerland
- Founders: Thomas Steinmüller, Dietmar Hold, Michael Forster
- Technology: Magnetically controlled nanoparticles for targeted drug delivery
- Compatibility: Up to 90% of all available cytostatics
- Shareholders: 120+
- Platform: Konsento (digital share register & corporate actions)
- Website: www.cantreat.ch